Tryptamine Therapeutics (ASX:TYP) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tryptamine Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Tryptamine Therapeutics's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Tryptamine Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tryptamine Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics LT-Debt-to-Total-Asset Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.04

0.02

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial						0.04	0.02	-	-	-

Tryptamine Therapeutics LT-Debt-to-Total-Asset Calculation

Tryptamine Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	0	/	5.881
	=	0.00

Tryptamine Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	3.083
	=

Tryptamine Therapeutics (ASX:TYP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tryptamine Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines